Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway

Zhao,Xudong; Wang,Xietong

doi:10.3892/mmr.2018.9070

Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway

Authors:
- Xudong Zhao
- Xietong Wang
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: May 23, 2018 https://doi.org/10.3892/mmr.2018.9070
Pages: 705-714
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypertensive disorders may be a complication of pregnancy and are characterized by the high blood pressure. Evidence suggests that alterations in the renin‑angiotensin‑aldosterone system and the sympathetic nervous system are associated with gestational hypertension. Angiotensin II type 1 receptor (Ang‑IITR) is a potential target in the progression of gestational hypertension. Candesartan is selective Ang‑IITR antagonist that may act against vasoconstriction and reduces peripheral vascular resistance. The aim of the present study was to evaluate the efficacy of Candesartan and the underlying molecular mechanism of the nuclear factor‑κB (NF‑κB) signaling pathway in the progression of gestational hypertension in a mouse model. Expression and activity of Ang‑IITR was evaluated in a mouse model of gestational hypertension prior to and post‑treatment of Candesartan both in vitro and in vivo. It was determined whether Candesartan treatment reduces higher blood pressure activated the renal renin‑angiotensin system and a prognostic marker, soluble endoglin, and its associated gene in mice with gestational hypertension. Angiotensin‑converting enzyme plasma levels and activity were also evaluated in the present study. Cytoplasmic and nuclear immunostaining of NF‑κB and associated proteins transforming growth factor β (TGF‑β) and endoglin was enhanced in vascular endothelial cells and mice with gestational hypertension. Soluble fms‑like tyrosine kinase 1 (sFlt‑1), insulin resistance homeostasis model assessment score and associated cardiovascular risk factors also were measured. Results demonstrated that angiotensin and Ang‑IITR expression levels were upregulated in mice with gestational hypertension and were downregulated by Candesartan treatment. Renal renin‑angiotensin and soluble endoglin were also improved in mice in the Candesartan‑treated group. In addition, Candesartan treatment enhanced NF‑κB activity, as well as TGF‑β and vascular endothelial growth factor expression which led to improved levels of sFlt‑1, insulin resistance homeostasis and associated cardiovascular risk factors. Gestational hypertension was markedly improved by treatment of Candesartan compared with the control. In conclusion, the findings of the present study suggested that the NF‑κB signaling pathway may be involved in with Candesartan‑mediated Ang‑IITR for the treatment of gestational hypertension.

View Figures

View References

1	Kennedy DA, Woodland C and Koren G: Lead exposure, gestational hypertension and pre-eclampsia: A systematic review of cause and effect. J Obstet Gynaecol. 32:512–517. 2012. View Article : Google Scholar : PubMed/NCBI
2	Huang YH, Chen YP, Liang CC, Chang YL and Hsieh CC: Impetigo herpetiformis with gestational hypertension: A case report and literature review. Dermatology. 222:221–224. 2011. View Article : Google Scholar : PubMed/NCBI
3	Razi Mohamad ZR and Schindler AE: Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension. Horm Mol Biol Clin Investig. 27:73–76. 2016.PubMed/NCBI
4	Pengo MF, Rossi GP and Steier J: Obstructive sleep apnea, gestational hypertension and preeclampsia: A review of the literature. Curr Opin Pulm Med. 20:588–594. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhu YC, Sun Y and Yang HX: Chronic hypertension superimposed on preeclampsia at 13 gestational weeks: A case report with review. Chin Med J(Engl). 125:2067–2069. 2012.PubMed/NCBI
6	Grandone E, Margaglione M, Colaizzo D, Cappucci G, Sciannamé N, Montanaro S, Paladini D, Martinelli P and Di Minno G: Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost. 81:349–352. 1999. View Article : Google Scholar : PubMed/NCBI
7	Vasapollo B, Novelli GP, Gagliardi G, Tiralongo GM, Pisani I, Manfellotto D, Giannini L and Valensise H: Medical treatment of early-onset mild gestational hypertension reduces total peripheral vascular resistance and influences maternal and fetal complications. Ultrasound Obstet Gynecol. 40:325–331. 2012. View Article : Google Scholar : PubMed/NCBI
8	Banhidy F, Acs N, Puho EH and Czeizel AE: The efficacy of antihypertensive treatment in pregnant women with chronic and gestational hypertension: A population-based study. Hypertens Res. 33:460–466. 2010. View Article : Google Scholar : PubMed/NCBI
9	Schoenaker DA, Soedamah-Muthu SS and Mishra GD: The association between dietary factors and gestational hypertension and pre-eclampsia: A systematic review and meta-analysis of observational studies. BMC Med. 12:1572014. View Article : Google Scholar : PubMed/NCBI
10	Rashid Zainul MR, Lim JF, Nawawi NH, Luqman M, Zolkeplai MF, Rangkuty HS, Nor Mohamad NA, Tamil A, Shah SA, Tham SW and Schindler AE: A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae. Gynecol Endocrinol. 30:217–220. 2014. View Article : Google Scholar : PubMed/NCBI
11	Wang YA, Chughtai AA, Farquhar CM, Pollock W, Lui K and Sullivan EA: Increased incidence of gestational hypertension and preeclampsia after assisted reproductive technology treatment. Fertil Steril. 105:920–926, e922. 2016. View Article : Google Scholar : PubMed/NCBI
12	Hua X, Zhang J, Guo Y, Shen M, Gaudet L, Janoudi G, Walker M and Wen SW: Effect of folic acid supplementation during pregnancy on gestational hypertension/preeclampsia: A systematic review and meta-analysis. Hypertens Pregnancy. 35:447–460. 2016. View Article : Google Scholar : PubMed/NCBI
13	Basaran A, Basaran M, Topatan B and Martin JN Jr: Effect of chorionic villus sampling on the occurrence of preeclampsia and gestational hypertension: An updated systematic review and meta-analysis. J Turk Ger Gynecol Assoc. 17:65–72. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chinnathambi V, More AS, Hankins GD, Yallampalli C and Sathishkumar K: Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats. Biol Reprod. 91:62014. View Article : Google Scholar : PubMed/NCBI
15	Seremak-Mrozikiewicz A, Drews K, Chmara E, Mrozikiewicz PM and Slomko Z: Gestational hypertension (GH) and a1166c polymorphism of angiotensin II type 1 receptor. Ginekol Pol. 71:783–788. 2000.(In Polish). PubMed/NCBI
16	Chen PM, Lai TS, Chen PY, Lai CF, Wu V, Chiang WC, Chen YM, Wu KD and Tsai TJ: Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. J Formos Med Assoc. 113:219–226. 2014. View Article : Google Scholar : PubMed/NCBI
17	Mavrakanas TA, Gariani K and Martin PY: Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy: A systematic review. Eur J Intern Med. 25:173–176. 2014. View Article : Google Scholar : PubMed/NCBI
18	Tsutamoto T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T and Horie M: Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res. 33:118–122. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U and Russell D: Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens. 24:263–273. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fogari R, Zoppi A, Salvadeo SA, Mugellini A, Lazzari P, Santoro T and Derosa G: Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. Hypertens Res. 34:509–515. 2011. View Article : Google Scholar : PubMed/NCBI
21	Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N and Asai S: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: A retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 9:382010. View Article : Google Scholar : PubMed/NCBI
22	Wai-Hoe L, Wing-Seng L, Ismail Z and Lay-Harn G: SDS-PAGE-Based quantitative assay for screening of kidney stone disease. Biol Proced Online. 11:145–160. 2009. View Article : Google Scholar : PubMed/NCBI
23	Armstrong DW, Tse MY, O'Tierney-Ginn PF, Wong PG, Ventura NM, Janzen-Pang JJ, Matangi MF, Johri AM, Croy BA, Adams MA and Pang SC: Gestational hypertension in atrial natriuretic peptide knockout mice and the developmental origins of salt-sensitivity and cardiac hypertrophy. Regul Pept. 186:108–115. 2013. View Article : Google Scholar : PubMed/NCBI
24	Partyka R, Chmiel B, Sikora J, Grabowska T, Wróbel B, Praisner A, Pióro A, Jałowieicki P and Kokocinska D: Lipofuscin, homocysteine and tissue polypeptide specific antigen in gestational hypertension. Neuro Endocrinol Lett. 28:311–314. 2007.PubMed/NCBI
25	Xiao S, Wang J and Xiao N: MicroRNAs as noninvasive biomarkers in bladder cancer detection: A diagnostic meta-analysis based on qRT-PCR data. Int J Biol Markers. 31:e276–e285. 2016. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Yang L, Zhang W, Zhang L, Zhang S, Yang Y, Wang Q, Shao J, Chen G and Wang Y: Gestational hypertension risk evaluation based on epidemiological, biochemical, and hemodynamic factors. Clin Exp Obstet Gynecol. 40:61–65. 2013.PubMed/NCBI
28	Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV and Brown NJ: Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension. 51:454–459. 2008. View Article : Google Scholar : PubMed/NCBI
29	Iwatsubo K and Umemura S: Alpha adrenergic receptor blockers for patients with hypertension. Nihon Rinsho. 64 Suppl 6:S294–S299. 2006.(In Japanese).
30	Mancia G: Introduction to a compendium on hypertension. Circ Res. 116:923–924. 2015. View Article : Google Scholar : PubMed/NCBI
31	Davidovich IM, Bloshchinskaia IA and Petrichko TA: Gestational arterial hypertension. Mechanisms of formation. Treatment with normodipin. Ter Arkh. 75:50–54. 2003.(In Russian). PubMed/NCBI
32	Kong J and Li YC: Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am J Physiol Regul Integr Comp Physiol. 285:R255–R261. 2003. View Article : Google Scholar : PubMed/NCBI
33	Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, Koga H and Noguchi T: Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med. 35:1471–1478. 2009. View Article : Google Scholar : PubMed/NCBI
34	Rakusan K, Chvojkova Z, Oliviero P, Ostadalova I, Kolar F, Chassagne C, Samuel JL and Ostadal B: ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats. Am J Physiol Heart Circ Physiol. 292:H1237–H1244. 2007. View Article : Google Scholar : PubMed/NCBI
35	Yasuno S, Fujimoto A, Nakagawa Y, Kuwahara K and Ueshima K: Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther. 10:577–583. 2012. View Article : Google Scholar : PubMed/NCBI
36	Barrios V and Escobar C: Candesartan in the treatment of hypertension: What have we learnt in the last decade? Expert Opin Drug Saf. 10:957–968. 2011. View Article : Google Scholar : PubMed/NCBI
37	Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, Youn HJ and Kim JH: Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naive patients of hypertension. Hypertens Res. 36:79–84. 2013. View Article : Google Scholar : PubMed/NCBI
38	Henriksson M, Russell D, Bodegard J, Kjeldsen S, Hasvold P, Stålhammar J and Levin LÅ: Health-care costs of losartan and candesartan in the primary treatment of hypertension. J Hum Hypertens. 25:130–136. 2011. View Article : Google Scholar : PubMed/NCBI
39	Moltzer E, Raso Mattace FU, Karamermer Y, Boersma E, Webb GD, Simoons ML, Danser AH, van den Meiracker AH and Roos-Hesselink JW: Comparison of candesartan versus metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J Cardiol. 105:217–222. 2010. View Article : Google Scholar : PubMed/NCBI
40	Meredith PA, Murray LS and McInnes GT: Comparison of the efficacy of candesartan and losartan: A meta-analysis of trials in the treatment of hypertension. J Hum Hypertens. 24:525–531. 2010. View Article : Google Scholar : PubMed/NCBI
41	Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H and Saruta T: CASE-J Trial Group: The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: A subanalysis of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res. 31:1595–1601. 2008. View Article : Google Scholar : PubMed/NCBI
42	Gu JW, Tian N, Shparago M, Tan W, Bailey AP and Manning RD Jr: Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 291:R1817–R1824. 2006. View Article : Google Scholar : PubMed/NCBI
43	Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW, Beasley MB, Hyman AL, Friedman M and Kadowitz PJ: Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol. 282:L1209–L1221. 2002. View Article : Google Scholar : PubMed/NCBI
44	Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, et al: Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res. 101:268–276. 2007. View Article : Google Scholar : PubMed/NCBI
45	Alonso F, Krattinger N, Mazzolai L, Simon A, Waeber G, Meda P and Haefliger JA: An angiotensin II- and NF-kappaB-dependent mechanism increases connexin 43 in murine arteries targeted by renin-dependent hypertension. Cardiovasc Res. 87:166–176. 2010. View Article : Google Scholar : PubMed/NCBI
46	Purkayastha S, Zhang G and Cai D: Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-β and NFκB. Nat Med. 17:883–887. 2011. View Article : Google Scholar : PubMed/NCBI
47	Li XW, Guo B, Shen YY and Yang JR: Effect of chrysin on expression of NOX4 and NF-kappaB in right ventricle of monocrotaline-induced pulmonary arterial hypertension of rats. Yao Xue Xue Bao. 50:1128–1134. 2015.(In Chinese). PubMed/NCBI
48	Carney EF: Hypertension: sFlt-1 removal seems to be beneficial in women with pre-eclampsia. Nat Rev Nephrol. 11:6902015. View Article : Google Scholar
49	Valbuena-Diez AC, Blanco FJ, Oujo B, Langa C, Gonzalez-Nuñez M, Llano E, Pendas AM, Díaz M, Castrillo A, Lopez-Novoa JM and Bernabeu C: Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation. 126:2612–2624. 2012. View Article : Google Scholar : PubMed/NCBI
50	Daly AL, Robertson A, Johnson P, Middleton S, Bobek G, Sullivan C and Hennessy A: PP162. sFlt-1 controlled by CPAP in a pregnant patient with chronic hypertension. Pregnancy Hypertens. 2:3272012. View Article : Google Scholar : PubMed/NCBI
51	Gluchowska M, Kowalska-Koprek U and Karowicz-Bilińska A: Evaluation of the usefulness of endoglin level as a predictor of preeclampsia in pregnant women with hypertension. Ginekol Pol. 84:835–840. 2013.(In Polish). View Article : Google Scholar : PubMed/NCBI
52	Muda P, Kampus P, Teesalu R, Zilmer K, Ristimäe T, Fischer K and Zilmer M: Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. Blood Press. 15:313–318. 2006. View Article : Google Scholar : PubMed/NCBI
53	Ikeda H, Inoue T, Uemura S, Kaibara R, Tanaka H and Node K: Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms. Hypertens Res. 29:1007–1012. 2006. View Article : Google Scholar : PubMed/NCBI
54	Nzelu D, Dumitrascu-Biris D, Hunt KF, Cordina M and Kametas NA: Pregnancy outcomes in women with previous gestational hypertension: A cohort study to guide counselling and management. Pregnancy Hypertens. 2017. View Article : Google Scholar
55	Pauli JM, Lauring JR, Stetter CM, Repke JT, Botti JJ, Ural SH and Ambrose A: Management of gestational hypertension-the impact of HYPITATa. J Perinat Med. 41:415–420. 2013. View Article : Google Scholar : PubMed/NCBI
56	Sibai BM: Management of late preterm and early-term pregnancies complicated by mild gestational hypertension/pre-eclampsia. Semin Perinatol. 35:292–296. 2011. View Article : Google Scholar : PubMed/NCBI